Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Evofem Biosciences, Inc. (EVFM) had Return on Tangible Equity of -1.34% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.84M |
|
$0.95M |
|
$0.36M |
|
$0.48M |
|
$0.52M |
|
$0.33M |
|
$0.63M |
|
$0.96M |
|
$0.96M |
|
$0.96M |
|
$0.96M |
|
$0.96M |
|
$0.96M |
|
$0.33M |
|
$0.59M |
|
113.36M |
|
6.04B |
|
$0.01 |
|
$0.00 |
|
| Balance Sheet Financials | |
$5.87M |
|
$0.43M |
|
$7.00M |
|
$12.88M |
|
$70.85M |
|
-- |
|
$6.83M |
|
$77.68M |
|
$-69.59M |
|
$-71.29M |
|
$-64.80M |
|
113.36M |
|
| Cash Flow Statement Financials | |
$0.56M |
|
$-0.06M |
|
$-0.14M |
|
$0.74M |
|
$1.11M |
|
$0.37M |
|
$0.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.08 |
|
-- |
|
-- |
|
-- |
|
-0.70 |
|
56.80% |
|
38.70% |
|
38.70% |
|
-- |
|
113.14% |
|
112.78% |
|
$0.50M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.16 |
|
0.74 |
|
122.38 |
|
-1.37% |
|
|
Return on Tangible Equity |
-1.34% |
7.42% |
|
-1.48% |
|
$-0.57 |
|
$0.00 |
|
$0.00 |
|